符合法规和指南要求的生物样本分析

用于新药申报的生物样本分析过程需要接受药政管理部门的严格监管，以往的研究结果提示，我国的生物样本分析质量还存在很大的提高空间。本文回顾了国内外针对生物样本分析的法规和质量体系建设情况以及目前在生物样本分析的方法学开发、确证和测试等方面需要注意的问题，提醒有关人员注意提高生物样本分析的测试数据质量。

Analytical processes of biosamples for the marketing authorization of new drugs are strictly supervised by the state regulatory agents.Previous analytical results suggest that there is great room for improvement in data quality of bioanalysis carried out in our country.The present paper reviews the guidelines and the construction of quality system for the bioanalysis,as well as the problems required to be paid attention to in the method development,validation and assay of biosamples.The purpose of this review is to remind the people involved in bioanalysis of the importance of data quality.

[1] Zhou M.Regulated Bioanalytical Laboratories:Technical and Regulatory Aspects from Global Perspective[M].New Jersey:Willey,2011
[2] Cayen MN.Early Drug Development:Strategies and Routes to First-in-Human Trials[M].New Jersey:Willey,2010:131
[3] CFDA(国家食品药品管理局).Guideline on the Non-clinical Pharmacokinetic Study of Chemical Drugs(化学药物非临床药代动力学研究技术指导原则)[S].2005
[4] CFDA(国家食品药品管理局).Guideline on the Clinical Pharmacokinetic Study of Chemical Drugs(化学药物临床药代动力学研究技术指导原则)[S].2005
[5] CFDA(国家食品药品管理局).Guideline on the Human Bioavailability and Bioequivalence of Chemical Drug Preparations(化学药物制剂人体生物利用度和生物等效性研究技术指导原则) [S].2005
[6] XU Ping(徐萍),ZHU Yun-gui(朱运贵),ZHANG Bi-kui(张毕奎),et al.Bioequivalence of 2 amlodipine besylate tablets by LC-MS/MS in healthy Chinese volunteers(LC-MS/MS法评价2种苯磺酸氨氯地平的生物等效性)[J].Cent South Pharm(中南药学),2008,6(3):286
[7] MA Tao(马涛),ZHANG Zhi-tao(张志涛),WANG Qing-qing(王清清),et al.Bioequivalence of amlodipine besylate tablets in healthy volunteers(苯磺酸氨氯地平片人体生物等效性研究)[J].J Bengbu Med Coll(蚌埠医学院学报),2008,33(3):344
[8] LI Xi(李茜),DENG Jun-gang(邓俊刚),QIAO Jian(乔建),et al.Study on the relative bioavailability and bioequivalence of lansoprazol tablets(兰索拉唑片相对生物利用度与生物等效性研究)[J]. Her Med(医药导报),2009,28(2):165
[9] CHEN Wei-li(陈伟力),LI Xue-ning(李雪宁),XU Hong-rong(徐红蓉),et al.Bioequivalence of lansoprazole and its metabolites(兰索拉唑及其代谢物生物等效性)[J].Chin J Clin Pharm(中国临床药学杂志),2005,14(6):351
[10] Food and Drug Administration.Guidance for Industry:Bioanalytical Method Validation[S].2013(draft)
[11] European Medicines Agency.Guideline on Bioanalytical Method Validation[S].2012
[12] U.S.Department of Health and Human Services.Good Laboratory Practice for Nonclinical Laboratory Studies[S].Code of Federal Regulation,21 CFR Part 58
[13] Organization for Economic Co-operation and Development.OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring[S].No 1
[14] CFDA(国家食品药品管理局).Good Laboratory Practice for Nonclinical Laboratory Studies(药物非临床研究质量管理规范)[S].2003
[15] Ezzelle J,Rodriguez-Chavez IR,Darden JM,et al.Guidelines on good clinical laboratory practice:bridging operations between research and clinical research laboratories[J].J Pharm Biomed Anal,2008,46(1):18
[16] CFDA(国家食品药品管理局).Laboratory Administrative Regulations for the Analysis of Biosamples from Clinical Trials(Provisional) [S].2011
[17] LIU Chang-xiao(刘昌孝).Practice Pharmacokinetics(实用药物动力学)[M].Beijing(北京):China Medical Science Press(中国医药科技出版社),2003:335
[18] LI Hao-zhi(李好枝).In Vivo Drug Analysis(体内药物分析)[M].Beijing(北京):People's Medical Publishing House(人民卫生出版社),2008:48
[19] Lee MS,Zhu M.Mass Spectrometry in Drug Metabolism and Disposition:Basic Principles and Applications[M].New Jersey:Willey,2011:613
[20] Khan MN,Findlay JWA.Ligand-binding Assays:Development,Validation,and Implementation in the Drug Development Area[M].New Jersey:Willey,2010:15
[21] Nowatzke W,Woolf E.Best practice during bioanalytical method validation for the characterization of assay regents and the evaluation of analyte stability in assay standards,quality controls,and study samples[J].AAPS J,2007,9(2):E117
[22] WEI Min-ji(魏敏吉),ZHANG Yu-hu(张玉琥),ZHANG Zhe-feng(张哲峰).Accuracy Problems During the Analysis of Biosamples and Disscusion on the Improving Measures(生物样品分析中存在的准确性问题和改进措施探讨).2012-04-11.http://www.cde.org.cn/dzkw.do?method=largePage&id=312642
[23] European Medicines Agency.Guideline on the Investigation of Bioequivalence[S].2010
[24] Viswanathan CT,Bansal S,Booth B,et al.Quantitative bioanalytical methods validation and implementation:best practices for chromatographic and ligand binding assays[J].Pharm Res,2007,24(10):1962